All articles starting with N
16,460 articles
NCI-H647
NCI-H647 (H647, CVCL_1574, ATCC CRL-5834) is a human lung cancer cell line from a 56-year-old male with stage 3A adenosquamous carcinoma, established 1983 from pleural effusion; KRAS Gly13Asp, TP53 splice mutant, used in NSCLC and drug-screening research.
NCI-H650
NCI-H650 (H650, CVCL_1575) is a human lung adenocarcinoma cell line from a male with bronchioalveolar carcinoma, established 1983 by Gazdar and Minna; KRAS Q61L and TP53 K164N homozygous, microsatellite stable, floating spherical growth.
NCI-H660
NCI-H660 (CVCL_1576, ATCC CRL-5813) is a human epithelial neuroendocrine cancer cell line from a cervical lymph node metastasis of prostate small cell carcinoma in a 63-year-old man; AR-negative, TMPRSS2-ERG fusion-positive, suspension-growing model of neuroendocrine prostate cancer.
NCI-H661
NCI-H661 (H661, CVCL_1577, ATCC HTB-183) is a human NSCLC large cell carcinoma cell line derived in 1982 from a 43-year-old male's lymph node metastasis, TP53- and CDKN2A-mutant, EGFR wild-type.
NCI-H69
NCI-H69 (H69, HTB-119, CVCL_1579) is a human small cell lung cancer cell line from a 55-year-old man's pleural effusion, N-myc amplified, RB1/TP53 mutant, parent of drug-resistant variants H69AR and H69/LX4.
NCI-H716
NCI-H716 (H716, ATCC CCL-251) is a human cecal colorectal adenocarcinoma cell line, suspension-growing and hypotriploid, used as the main model of human intestinal L cells for GLP-1 secretion and notable for FGFR2 amplification.
NCI-H720
NCI-H720 (H720, CVCL_1583, ATCC CRL-5838) is a human lung carcinoid cell line from a male with atypical carcinoid, established 1984 by Gazdar and Minna; suspension-growing, TP53 and RB1 mutant, standard AC model paired with NCI-H727.
NCI-H727
NCI-H727 is a human cancer cell line derived from a bronchial carcinoid lung tumor, established in 1984 and widely used as a research model of pulmonary neuroendocrine tumors.
NCI-H747
NCI-H747 (H747, CVCL_1587) is a human colorectal adenocarcinoma cell line from the cecum of a 69-year-old male, derived from a lymph node metastasis, carrying APC, KRAS G13D, and TP53 mutations, available as ATCC CCL-252.
NCI-H748
NCI-H748 (H748, CVCL_1588, ATCC CRL-5841) is a human small cell lung cancer cell line from a 62-year-old African American man's lymph node metastasis, carrying TP53, RB1, and BRCA2 mutations, used in SCLC pharmacogenomic and drug screening studies.
NCI-H774
NCI-H774 (H774, CVCL_1589, ATCC CRL-5842) is a human small cell lung cancer cell line established in 1984 from a 43-year-old male smoker's soft-tissue metastasis; suspension-growing, TP53 R342, MAP2K4-deleted.
NCI-H810
NCI-H810 (H810, CVCL_1590, ATCC CRL-5816) is a human lung large cell/non-small cell lung cancer cell line from a 51-year-old Black male, TP53 and DDR2 mutant, NMB/GRP non-synthesizing, used in cancer research.
NCI-H82
NCI-H82 (H82, CVCL_1591) is a human small cell lung carcinoma cell line derived in 1978 by Gazdar from a male patient's pleural effusion; a variant SCLC model with ~25-fold c-myc amplification, suspension growth, and TP53 splicing mutation.
NCI-H820
NCI-H820 (H820, CVCL_1592, ATCC HTB-181) is a human lung papillary adenocarcinoma cell line derived in 1984 by Gazdar and Oie from a supraclavicular lymph node metastasis, notable for TP53 Thr284Pro and dual EGFR activating/T790M mutations.
NCI-H838
NCI-H838, also written H838, is a human lung adenocarcinoma cell line established in 1984 from a 59-year-old male smoker, and is widely used in lung cancer research.
NCI-H841
NCI-H841 (H841, CVCL_1595, ATCC CRL-5845) is a human lung cancer cell line established in 1984, originally variant small cell lung cancer, reclassified in 2024 as a thoracic SMARCA4-deficient undifferentiated tumor with homozygous SMARCA4 and TP53 mutations.
NCI-H847
NCI-H847 (NCIH847, H847; CVCL_1596) is a human small cell lung cancer cell line established in 1984 from a 63-year-old man's metastatic pleural effusion, ATCC CRL-5846, TP53 R158L, used in NCI SCLC pharmacogenomic panels.
NCI-H889
NCI-H889 (H889, CVCL_1598) is a human small cell lung cancer cell line from a lymph node metastasis in a 69-year-old White female, derived by Gazdar, Oie, and Minna; TP53 p.Cys242Ser, suspension clusters, ATCC CRL-5817.
NCI-H920
NCI-H920 (H920, CVCL_1599, ATCC CRL-5850) is a human lung adenocarcinoma cell line established in December 1984 from a 43-year-old male 75 pack-year smoker; NSCLC stage 4 model with TP53 c.560-1G>T, floating-aggregate growth, and extensive omics data.
NCI-H929
NCI-H929 (H929, CVCL_1600) is a human IgA kappa multiple myeloma cell line established in 1986 from a pleural effusion, with rearranged c-myc, NRAS Gly13Asp, EBV-negative, held at ATCC CRL-3580 and DSMZ ACC-163.
NCI-N231
NCI-N231 (N231, NCI-H231, CVCL_A788) is a human small cell lung cancer cell line established in 1980 from a mouse xenograft, female, carrying a TP53 p.Glu298Ter nonsense mutation, used in SCLC drug-sensitivity research.
NCI-N87
NCI-N87, also written N87, is a human gastric cancer cell line created at the National Cancer Institute in 1976 from a liver metastasis of a stomach carcinoma.
nCino, Inc.
nCino, Inc. is an American software company founded in 2011 and headquartered in Wilmington, North Carolina, offering a cloud-based platform that digitizes onboarding, loan origination, and account opening for banks.
NCIS (franchise)
NCIS franchise: American crime-procedural TV universe spun off from JAG (1995-2005); flagship NCIS premiered on CBS September 23, 2003, created by Donald P. Bellisario, spawning Los Angeles, New Orleans, Hawai'i, Sydney, Origins, Tony & Ziva, and New York.
NCIS (TV series)
NCIS (also Navy CIS, Navy NCIS) is an American CBS crime drama premiering September 23, 2003, created by Donald P. Bellisario from a JAG backdoor pilot, following Naval Criminal Investigative Service agents; 24 seasons, four spin-offs, long CBS's No. 1 drama.
NCIS crossover event
NCIS crossover event: multi-episode shared storylines across the NCIS franchise and JAG, from the JAG Season 8 backdoor pilot through the 2023 three-show event and the 2025 NCIS/NCIS: Origins Veterans Day crossover.
NCIS season 21
NCIS season 21 is the 2024, 10-episode strike-shortened CBS season, premiering February 12, 2024 with "Algún Día", featuring the Ducky tribute episode, Michael Weatherly's return as Tony DiNozzo, and the finale "Reef Madness" that set up the Lily mystery.
NCIS season 22
NCIS season 22, the 2024-2025 CBS run of the Naval Criminal Investigative Service crime drama, premiered October 14, 2024, ran 20 episodes ending with "Nexus", kept its seven-actor cast unchanged, and opened to 6.4 million viewers.
NCIS season 23
NCIS season 23 is the 2025-26 CBS run of the Naval Criminal Investigative Service procedural, 20 episodes following Alden Parker's revenge arc against Carla Marino, the franchise's 500th episode, and a Veterans Day Origins crossover.
NCIS season 24
NCIS season 24 (premiering October 6, 2026, on CBS) is the 24th season of the Naval Criminal Investigative Service procedural drama, notable for Michael Weatherly's return as Tony DiNozzo after ten years and Sean Murray's 500th episode.